Nielsen, a global measurement and data analytics company, recently revealed that direct-to-consumer healthcare advertising has reached 75% of US cancer survivors on television.
Nielsen, a global measurement and data analytics company, recently revealed that direct-to-consumer (DTC) healthcare advertising has reached 75% of US cancer survivors on television.
“Survivors will look to many sources to increase their knowledge about the disease, become more informed about treatment options and learn about ways to reduce future risk of recurrence,” according to Neilsen. The report also states that the sources individuals value most are linked with how long they have had their diagnoses.
Those who have been diagnosed for 1 to 2 years are more alert to healthcare advertising, according to Nielsen, than average cancer survivors. This group is 28% more likely than the average survivor to report having seen advertising at a pharmacy, 23% more likely to report having seen ads on the internet, and 15% more likely to report having seen ads in direct mail. They are also 35% more likely to value information that they read in newspaper advertising than in other media.
Nielsen also indicates that this group of survivors is more likely than the average cancer survivor to ask their physicians to prescribe a specific drug as a result of having seen healthcare advertising.
Such numbers are of particular interest given the Trump administration’s push to require DTC television advertisements for drugs to contain drug pricing information. The proposal, which is part of the administration’s focus on curbing the increasing price of drugs, has been met with resistance from drug makers; According to Stephen Ubl, president and CEO of the trade group Pharmaceutical Research and Manufacturers of America, disclosing the list price in TV advertisements may discourage patients from seeking needed medical care. Ubl also noted that if a requirement was implemented to disclose such information it would “raise significant legal issues, including First Amendment concerns.”
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
August 22nd 2024Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.